Literature DB >> 20095989

Secondary and tertiary structure modeling reveals effects of novel mutations in polycystic liver disease genes PRKCSH and SEC63.

E Waanders1, H Venselaar, R H M te Morsche, D B de Koning, P S Kamath, V E Torres, S Somlo, J P H Drenth.   

Abstract

Polycystic liver disease (PCLD) is characterized by intralobular bile duct cysts in the liver. It is caused by mutations in PRKCSH, encoding hepatocystin, and SEC63, encoding Sec63p. The main goals of this study were to screen for novel mutations and to analyze mutations for effects on protein structure and function. We screened 464 subjects including 76 probands by direct sequencing or conformation-sensitive capillary electrophoresis. We analyzed the effects of all known and novel mutations using a combination of splice site recognition, evolutionary conservation, secondary and tertiary structure predictions, PolyPhen, and pMut and sift. We identified a total of 26 novel mutations in PRKCSH (n = 14) and SEC63 (n = 12), including four splice site mutations, eight insertions/ deletions, six non-sense mutations, and eight missense mutations. Out of 48 PCLD mutations, 13 were predicted to affect splicing. Most mutations were located in highly conserved regions and homology modeling for two domains of Sec63p showed severe effects of the residue substitutions. In conclusion, we identified 26 novel mutations associated with PCLD and we provide in silico analysis in order to delineate the role of these mutations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20095989      PMCID: PMC4127811          DOI: 10.1111/j.1399-0004.2009.01353.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  31 in total

1.  The PSIPRED protein structure prediction server.

Authors:  L J McGuffin; K Bryson; D T Jones
Journal:  Bioinformatics       Date:  2000-04       Impact factor: 6.937

2.  Proteins of the endoplasmic-reticulum-associated degradation pathway: domain detection and function prediction.

Authors:  C P Ponting
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

3.  Quaternary and domain structure of glycoprotein processing glucosidase II.

Authors:  E S Trombetta; K G Fleming; A Helenius
Journal:  Biochemistry       Date:  2001-09-04       Impact factor: 3.162

4.  Increasing the precision of comparative models with YASARA NOVA--a self-parameterizing force field.

Authors:  Elmar Krieger; Günther Koraimann; Gert Vriend
Journal:  Proteins       Date:  2002-05-15

5.  Polycystic liver disease is genetically heterogeneous: clinical and linkage studies in eight Finnish families.

Authors:  Pia Tahvanainen; Esa Tahvanainen; Hanna Reijonen; Leena Halme; Helena Kääriäinen; Krister Höckerstedt
Journal:  J Hepatol       Date:  2003-01       Impact factor: 25.083

6.  Mammalian Sec61 is associated with Sec62 and Sec63.

Authors:  H A Meyer; H Grau; R Kraft; S Kostka; S Prehn; K U Kalies; E Hartmann
Journal:  J Biol Chem       Date:  2000-05-12       Impact factor: 5.157

7.  Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells.

Authors:  C Nguyen; G Liang; T T Nguyen; D Tsao-Wei; S Groshen; M Lübbert; J H Zhou; W F Benedict; P A Jones
Journal:  J Natl Cancer Inst       Date:  2001-10-03       Impact factor: 13.506

8.  Human non-synonymous SNPs: server and survey.

Authors:  Vasily Ramensky; Peer Bork; Shamil Sunyaev
Journal:  Nucleic Acids Res       Date:  2002-09-01       Impact factor: 16.971

9.  PRKCSH/80K-H, the protein mutated in polycystic liver disease, protects polycystin-2/TRPP2 against HERP-mediated degradation.

Authors:  Hongyu Gao; Yan Wang; Tomasz Wegierski; Kassiani Skouloudaki; Michael Pütz; Xiao Fu; Christina Engel; Christopher Boehlke; Hongquan Peng; E Wolfgang Kuehn; Emily Kim; Albrecht Kramer-Zucker; Gerd Walz
Journal:  Hum Mol Genet       Date:  2010-01-01       Impact factor: 6.150

10.  Clinical profile of autosomal dominant polycystic liver disease.

Authors:  Qi Qian; Airong Li; Bernard F King; Patrick S Kamath; Donna J Lager; John Huston; Clarence Shub; Sonia Davila; Stefan Somlo; Vicente E Torres
Journal:  Hepatology       Date:  2003-01       Impact factor: 17.425

View more
  16 in total

Review 1.  Evaluation of hepatic cystic lesions.

Authors:  Marten A Lantinga; Tom J G Gevers; Joost P H Drenth
Journal:  World J Gastroenterol       Date:  2013-06-21       Impact factor: 5.742

Review 2.  Polycystic liver diseases: advanced insights into the molecular mechanisms.

Authors:  Maria J Perugorria; Tatyana V Masyuk; Jose J Marin; Marco Marzioni; Luis Bujanda; Nicholas F LaRusso; Jesus M Banales
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-09-30       Impact factor: 46.802

Review 3.  Diagnosis and management of polycystic liver disease.

Authors:  Tom J G Gevers; Joost P H Drenth
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-01-08       Impact factor: 46.802

4.  Waitlisted Candidates With Polycystic Liver Disease Are More Likely to be Transplanted Than Those With Chronic Liver Failure.

Authors:  Sahil D Doshi; Therese Bittermann; Thomas D Schiano; David Seth Goldberg
Journal:  Transplantation       Date:  2017-08       Impact factor: 4.939

Review 5.  Current management of noninfectious hepatic cystic lesions: A review of the literature.

Authors:  Francisco Igor Macedo
Journal:  World J Hepatol       Date:  2013-09-27

6.  Boy with autosomal recessive polycystic kidney and autosomal dominant polycystic liver disease.

Authors:  Andrea Zingg-Schenk; Jürg Caduff; Silvia Azzarello-Burri; Carsten Bergmann; Joost P H Drenth; Thomas J Neuhaus
Journal:  Pediatr Nephrol       Date:  2012-03-14       Impact factor: 3.714

7.  Severe Polycystic Liver Disease Is Not Caused by Large Deletions of the PRKCSH Gene.

Authors:  Wybrich R Cnossen; Jake S F Maurits; Jody Salomon; René H M Te Morsche; Esmé Waanders; Joost P H Drenth
Journal:  J Clin Lab Anal       Date:  2015-09-13       Impact factor: 2.352

Review 8.  Polycystin-1: a master regulator of intersecting cystic pathways.

Authors:  Sorin V Fedeles; Anna-Rachel Gallagher; Stefan Somlo
Journal:  Trends Mol Med       Date:  2014-01-31       Impact factor: 11.951

Review 9.  CYP1A1 and GSTP1 gene variations in breast cancer: a systematic review and case-control study.

Authors:  Sumaira Akhtar; Ishrat Mahjabeen; Zertashia Akram; Mahmood Akhtar Kayani
Journal:  Fam Cancer       Date:  2016-04       Impact factor: 2.375

10.  Mutation of sec63 in zebrafish causes defects in myelinated axons and liver pathology.

Authors:  Kelly R Monk; Matthew G Voas; Clara Franzini-Armstrong; Ian S Hakkinen; William S Talbot
Journal:  Dis Model Mech       Date:  2012-08-03       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.